CLINICAL TRIALS PROFILE FOR TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE
✉ Email this page to a colleague
All Clinical Trials for tipiracil hydrochloride; trifluridine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01955837 ↗ | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | Completed | Taiho Pharmaceutical Co., Ltd. | Phase 3 | 2013-09-01 | To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies. |
| NCT02654639 ↗ | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | Georgetown University | Phase 2 | 2016-02-01 | Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC |
| NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | Mayo Clinic | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT03297710 ↗ | TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2017-12-11 | This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tipiracil hydrochloride; trifluridine
Condition Name
| Condition Name for tipiracil hydrochloride; trifluridine | |
| Intervention | Trials |
| Metastatic Colorectal Cancer | 12 |
| Colorectal Cancer | 7 |
| Stage IV Colorectal Cancer AJCC v8 | 6 |
| Stage IVB Colorectal Cancer AJCC v8 | 6 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for tipiracil hydrochloride; trifluridine
Trials by Country
Clinical Trial Progress for tipiracil hydrochloride; trifluridine
Clinical Trial Phase
Clinical Trial Sponsors for tipiracil hydrochloride; trifluridine
Sponsor Name
